Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea

  • Kang, Bo Hyoung (Department of Pulmonary and Critical Care Medicine, Dong-A University Hospital, Dong-A University College of Medicine) ;
  • Jo, Kyung-Wook (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Shim, Tae Sun (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2016.08.04
  • Accepted : 2017.01.23
  • Published : 2017.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Fluoroquinolones are considered important substitutes for the treatment of tuberculosis. This study investigates the current status of fluoroquinolone for the treatment of tuberculosis. Methods: In 2009, a retrospective analysis was performed at one tertiary referral center for 953 patients diagnosed with tuberculosis. Results: A total of 226 patients (23.6%), who received fluoroquinolone at any time during treatment for tuberculosis, were enrolled in this study. The most common reasons for fluoroquinolone use were adverse events due to other anti-tuberculosis drugs (52.7%), drug resistance (23.5%), and underlying diseases (16.8%). Moxifloxacin (54.0%, 122/226) was the most commonly administered fluoroquinolone, followed by levofloxacin (36.3%, 82/226) and ofloxacin (9.7%, 22/226). The frequency of total adverse events from fluoroquinolone-containing anti-tuberculosis medication was 22.6%, whereas fluoroquinolone-related adverse events were estimated to be 2.2% (5/226). The most common fluoroquinolone-related adverse events were gastrointestinal problems (3.5%, 8/226). There were no significant differences in the treatment success rate between the fluoroquinolone and fluoroquinolone-$na{\ddot{i}}ve$ groups (78.3% vs. 78.4%, respectively). Conclusion: At our institution, fluoroquinolones are commonly used for the treatment of both multidrug-resistant tuberculosis and susceptible tuberculosis, especially as a substitute for adverse event-related drugs. Considering the low adverse event rates and the comparable treatment success rates, fluoroquinolones seem to be an invaluable drug for the treatment of tuberculosis.

Keywords

References

  1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. https://doi.org/10.1164/rccm.167.4.603
  2. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991;99:465-71. https://doi.org/10.1378/chest.99.2.465
  3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-7. https://doi.org/10.1164/rccm.200206-626OC
  4. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006;5:231-49. https://doi.org/10.1517/14740338.5.2.231
  5. Jacobs MR. Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr Pharm Des 2004;10:3213-20. https://doi.org/10.2174/1381612043383296
  6. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008;31:904-5. https://doi.org/10.1183/09031936.00159807
  7. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28. https://doi.org/10.1183/09031936.00073611
  8. Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol 2001;16:1028-32. https://doi.org/10.1046/j.1440-1746.2001.02570.x
  9. Yew WW, Chau CH, Wong PC, Lee J, Wong CF, Cheung SW, et al. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. Drugs Exp Clin Res 1995;21:79-83.
  10. Marra F, Marra CA, Moadebi S, Shi P, Elwood RK, Stark G, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005;128:1406-13. https://doi.org/10.1378/chest.128.3.1406
  11. Codecasa LR, Ferrara G, Ferrarese M, Morandi MA, Penati V, Lacchini C, et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 2006;100:1566-72. https://doi.org/10.1016/j.rmed.2006.01.002
  12. Roberts CH, Smith C, Breen R, Gadhok R, Murphy M, Aryee A, et al. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Int J Tuberc Lung Dis 2011;15:1275-6. https://doi.org/10.5588/ijtld.11.0352
  13. Carroll MW, Lee M, Cai Y, Hallahan CW, Shaw PA, Min JH, et al. Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis 2012;16:961-6. https://doi.org/10.5588/ijtld.11.0574
  14. Fung SL, Yan SW, Chau CH, Yew WW. Tolerance of moxifloxacin- containing regimens in the treatment of tuberculosis. Int J Tuberc Lung Dis 2012;16:282-3. https://doi.org/10.5588/ijtld.11.0600
  15. Yoon HE, Jeon YJ, Chung HW, Shin SJ, Hwang HS, Lee SJ, et al. Safety and efficacy of a quinolone-based regimen for treatment of tuberculosis in renal transplant recipients. Transplant Proc 2012;44:730-3. https://doi.org/10.1016/j.transproceed.2011.12.065
  16. Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DR, Kosterink JG, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011;38:888-94. https://doi.org/10.1183/09031936.00176610
  17. Klemens SP, Sharpe CA, Rogge MC, Cynamon MH. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994;38:1476-9. https://doi.org/10.1128/AAC.38.7.1476
  18. Tortoli E, Dionisio D, Fabbri C. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis , including resistant and multidrug-resistant strains. J Chemother 2004;16:334-6. https://doi.org/10.1179/joc.2004.16.4.334
  19. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183-9. https://doi.org/10.1016/S0140-6736(09)60333-0
  20. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-38.
  21. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8. https://doi.org/10.1164/rccm.200603-360OC
  22. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-4. https://doi.org/10.1164/rccm.200407-885OC
  23. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-6. https://doi.org/10.1164/rccm.200310-1380OC
  24. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-42. https://doi.org/10.1016/S1473-3099(03)00671-6
  25. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18. https://doi.org/10.2165/00003495-200161010-00002
  26. World Health Organization. WHO guidelines approved by the Guidelines Review Committee. Treatment of tuberculosis: guidelines. Geneva: World Health Organization; 2010.
  27. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003;15:66-70. https://doi.org/10.1179/joc.2003.15.1.66
  28. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003;37:1448-52. https://doi.org/10.1086/379328
  29. Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985;131:352-6.
  30. Chen TC, Lu PL, Lin CY, Lin WR, Chen YH. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011;15:e211-6. https://doi.org/10.1016/j.ijid.2010.11.008
  31. Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Lew WJ, et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007;11:319-24.

Cited by

  1. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study vol.20, pp.None, 2017, https://doi.org/10.1186/s12879-020-05157-6